fda bpc-157 warning not approved human use clinical trials safety regulatory status evidence bpc-157 for fda warning bpc-157 peptide not

**vials contain lyophilized powder which requires reconstitution

Knockout of mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 (mtGPAT1), a major hepatic glycerol-3-phosphate acyltransferase, decreased de novo DAG generation protecting mice from hepatic insulin resistance (195)

Reported Benefits of BPC157 Accelerated Injury Recovery: BPC157 has been associated with faster healing of tendons, ligaments, and muscles

Let's walk through the math

Athira Pharma (formerly M3 Biotechnology), the WSU spinout founded to commercialize Dihexa-derivative compounds, paid approximately $4 million in a False Claims Act settlement in January 2025 after a whistleblower exposed concealment of the research misconduct from federal grant agencies, and approximately $10 million in a separate class-action settlement to investors